Navigation Links
GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018
Date:12/1/2011

FARMINGTON, Conn., Dec. 1, 2011 /PRNewswire-iReach/ -- Global Information, Inc. presents "Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018"  by GlobalData.

(Photo:  http://photos.prnewswire.com/prnh/20111201/CG15993)

Polycystic ovarian syndrome (PCOS) is a common chronic disorder of the endocrine system in women. It mostly affects women of reproductive age (12-45 years old) and is thought to be one of the main causes of female subfertility. It is characterized by a heterogeneous appearance of anovulation, hyperandrogenemia, or secondary metabolic problems such as obesity, insulin resistance and so on.

Other names for this syndrome are polycystic ovary disease (PCOD), functional ovarian hyperandrogenism, Stein-Leventhal syndrome, ovarian hyperthecosis and sclerocystic ovary syndrome

Static growth in the PCOS Therapeutics Market in the Forecast Period

The global PCOS market was valued at $656m in 2010; GlobalData estimates the PCOS market to reach $804m by 2018 growing at a CAGR of 2.6% in the forecast period.

The rising prevalent population of co-morbid conditions such as diabetes, obesity and dyslipidemia are the key driver for the static growth in PCOS therapeutics market. The market does not have an approved drug. Treatment options include generic and off-label drugs which have lower efficacy profiles, which mean that both physician and patient satisfaction are low.

The etiology and pathology of PCOS is not clearly understood. Therefore it is difficult to identify the cause of the disease and develop a drug against it, which means that the current therapies rely on treating the symptoms rather than the diseas
'/>"/>

SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
2. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
3. A New Target in Polycystic Kidney Disease
4. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
5. NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
6. OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment
7. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
8. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
9. BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers
10. EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
11. For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Adaptive Biotechnologies, ... Sequencing (NGS) to profile the adaptive immune system, is ... as Chief Commercial Officer (CCO). The addition of ... recent key hires from leading global healthcare companies, including ... (General Counsel) from Genomic Health and Sean ...
(Date:9/16/2014)... Sept. 16, 2014 EHE International, the recognized leader ... physician network, today announced that David Abrams M.D . ... an EHE-certified preventive care center. Through David Abrams M.D ... region now have greater access to EHE,s preventive care programs ... is proud to add Dr. Abrams M.D. to its growing ...
(Date:9/16/2014)... , Sept. 16, 2014 QPID Health , ... to new headquarters in Boston and ... headquarters will be at 175 Franklin Street in ... marketing teams. QPID Health,s new Southern California ... Carlsbad.  The expansion will help meet the demands of customers ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... 3, 2010 Cardiogenesis Corporation (OTCQB: CGCP), a leading ... diffuse coronary artery disease, today reported financial results for ... 30, 2010. Revenue for the third quarter ... year third quarter revenue of $2,134,000.  Gross margin was ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), ... that it has expanded its Medisystems® in-center product portfolio ... to the terms of the strategic Agreement with Vasc-Alert ... in the United States.   Vasc-Alert, a ...
Cached Medicine Technology:Cardiogenesis Reports Third Quarter 2010 Results 2Cardiogenesis Reports Third Quarter 2010 Results 3Cardiogenesis Reports Third Quarter 2010 Results 4Cardiogenesis Reports Third Quarter 2010 Results 5Cardiogenesis Reports Third Quarter 2010 Results 6NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™ 2NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™ 3
(Date:9/17/2014)... September 17, 2014 ICS Learning Group, ... for Excellence in Training for the Best Use of ... based on an online operational safety training module that ... forklift operation. Using an approach that combined realistic ... module that was similar to a video game, including ...
(Date:9/17/2014)... September 17, 2014 MicroSourcing International, Inc., ... Process Outsourcing (BPO) services in the Philippines, announced today ... Senior Vice President – North America to further develop ... is a 15 year veteran of the offshore outsourcing ... helping companies, ranging in size from small businesses to ...
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 ... high throughput research solutions for drug development, today ... Module 3 (CM3) Reaction Screening System to both ... to the Texas community. Freeslate’s high throughput system ... area of reaction screening and optimization for small ...
(Date:9/17/2014)... Hallandale Beach, FL (PRWEB) September 17, 2014 ... products, is pleased to announce their newest addition to ... This conditioner is formulated with nourishing and beneficial ... jojoba oils to provide hair with ample moisture, while ... Volumizing Biotin Conditioner is formulated to complement the ...
(Date:9/17/2014)... 2014 1st-Dress.com, one of the most ... long bridesmaid dresses recently. All the fresh ... quality materials. Furthermore, they are offered at deeply discounted ... , The firm is striving to provide a ... its workers never compromises on style, quality and customer ...
Breaking Medicine News(10 mins):Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2Health News:MicroSourcing Appoints New Senior Vice President of North America 2Health News:Baylor University Selects Freeslate Reaction Screening System to Support New High Throughput Screening Lab 2Health News:Luxury Barber Adds New Regenepure Biotin Conditioner to Their Selection of Grooming Products 2Health News:2014 Long Bridesmaid Dresses Available Online At 1st-Dress.com 2
... interests and those of the pharmaceutical industry has got sharper ... a bill that would clothe the Food and Drug Administration ... two years before advertising a newly approved drug directly to ... powers to fine companies that fail to do post-approval studies ...
... the most malignant diseases which are responsible for number of ... on this subject. A new study suggests that true biological ... have been confounded by Dr. Tim Byers, of the University ... ,It is not due to the disparity in the access ...
... vigorous arguments never seem to leave the Hormone Replacement Therapy (HRT) ... ‘notoriety’. ,Yet say some experts, don’t be in a ... them, hormone replacement therapy may have led to the deaths of ... 1991. ,In an article said to be the first ...
... pain and agony begin to subside over Monday’s ghastly student massacre ... killer Cho Seung-Hui began to take form. , The ... any stronger than this point of time. At the same time, ... ,The fact that Cho was a ‘disturbed’ student was not ...
... from vegetable sources, is touted as a more eco-friendly fuel, ... use of ethanol could actually pose a threat to human ... that eco-friendly after all. The journey for ever is hitting ... the US shows that it could be damaging to human ...
... small percentage of food imported into the United States is ... of some form or the other. What happens to the ... ,Recently, the United States has been reeling under the effect ... This could also be due to lenient food laws in ...
Cached Medicine News:Health News:Moratorium Proposed on Advertisements of Newly Approved Drugs 2Health News:Expert Warn- Odds Still Stacked Against Hormone Replacement Therapy 2Health News:Expert Warn- Odds Still Stacked Against Hormone Replacement Therapy 3Health News:Virginia Tech. Shooter -Human Rights or Innocent Lives 2Health News:Ethanol Could Be Damaging for Human Health, New Study Says 2Health News:Ethanol Could Be Damaging for Human Health, New Study Says 3
XL STABI Hydrophilic Acrylic Lens....
TRIPODE Hydrophilic Acrylic Lens....
Biocryl™ Acrylic Foldable Lens....
The STAAR ELASTIMIDE lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
Medicine Products: